dc.contributor.author |
Salas, Lucas A. |
dc.contributor.author |
Villanueva Belmonte, Cristina |
dc.contributor.author |
Tajuddin, Salman Muhammad |
dc.contributor.author |
Amaral, André F.S. |
dc.contributor.author |
Fernández, Agustín F. |
dc.contributor.author |
Moore, Lee E. |
dc.contributor.author |
Carrato, Alfredo |
dc.contributor.author |
Tardón, Adonina |
dc.contributor.author |
Serra, Consol |
dc.contributor.author |
García Closas, Reina |
dc.contributor.author |
Basagaña Flores, Xavier |
dc.contributor.author |
Rothman, Nathaniel |
dc.contributor.author |
Silverman, Debra T. |
dc.contributor.author |
Cantor, Kenneth P |
dc.contributor.author |
Kogevinas, Manolis |
dc.contributor.author |
Real, Francisco X. |
dc.contributor.author |
Fraga, Mario F. |
dc.contributor.author |
Malats i Riera, Núria |
dc.date |
2014 |
dc.identifier.citation |
Salas LA, Villanueva CM, Tajuddin SM, Amaral AF, Fernandez AF, Moore LE et al. LINE-1 methylation in granulocyte DNA and trihalomethane exposure is associated with bladder cancer risk. Epigenetics. 2014 Nov; 9(11): 1532-9. DOI: 10.4161/15592294.2014.983377 |
dc.identifier.citation |
1559-2294 |
dc.identifier.citation |
http://dx.doi.org/10.4161/15592294.2014.983377 |
dc.identifier.uri |
http://hdl.handle.net/10230/34617 |
dc.format |
application/pdf |
dc.language.iso |
eng |
dc.publisher |
Taylor & Francis (Routledge) |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.rights |
© Taylor & Francis. This is an electronic version of an article published in Salas LA, Villanueva CM, Tajuddin SM, Amaral AF, Fernandez AF, Moore LE et al. LINE-1 methylation in granulocyte DNA and trihalomethane exposure is associated with bladder cancer risk. Epigenetics. 2014 Nov; 9(11): 1532-9. Epigenetics is available online at: www.tandfonline.com (http://dx.doi.org/10.4161/15592294.2014.983377) |
dc.rights |
http://creativecommons.org/licenses/by-nc/3.0/ |
dc.subject |
Granulòcits |
dc.subject |
ADN -- Metilació |
dc.subject |
Bufeta -- Càncer |
dc.title |
LINE-1 methylation in granulocyte DNA and trihalomethane exposure is associated with bladder cancer risk |
dc.type |
info:eu-repo/semantics/article |
dc.type |
info:eu-repo/semantics/publishedVersion |
dc.description.abstract |
DNA methylation changes contribute to bladder carcinogenesis. Trihalomethanes (THM), a class of disinfection by-products, are associated with increased urothelial bladder cancer (UBC) risk. THM exposure in animal models produces DNA hypomethylation. We evaluated the relationship of LINE-1 5-methylcytosine levels (LINE-1%5mC) as outcome of long-term THM exposure among controls and as an effect modifier in the association between THM exposure and UBC risk. We used a case-control study of UBC conducted in Spain. We obtained personal lifetime residential THM levels and measured LINE-1%5mC by pyrosequencing in granulocyte DNA from blood samples in 548 incident cases and 559 hospital controls. Two LINE-1%5mC clusters (above and below 64%) were identified through unsupervised hierarchical cluster analysis. The association between THM levels and LINE-1%5mC was evaluated with β regression analyses and logistic regression was used to estimate odds ratios (OR) adjusting for covariables. LINE-1%5mC change between percentiles 75(th) and 25(th) of THM levels was 1.8% (95% confidence interval (CI): 0.1, 3.4%) among controls. THM levels above vs. below the median (26 μg/L) were associated with increased UBC risk, OR = 1.86 (95% CI: 1.25, 2.75), overall and among subjects with low levels of LINE-1%5mC (n = 975), OR = 2.14 (95% CI: 1.39, 3.30), but not associated with UBC risk among subjects' high levels of LINE-1%5mC (n = 162), interaction P = 0.03. Results suggest a positive association between LINE-1%5mC and THM levels among controls, and LINE-1%5mC status may modify the association between UBC risk and THM exposure. Because reverse causation and chance cannot be ruled out, confirmation studies are warranted. |
dc.description.abstract |
This study was partially supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics (Contract NCI NO2-CP-11015); the Spanish Health Ministry (Fondo de Investigaciones Sanitarias–FIS, Instituto de Salud Carlos III, Spain 00/0745, ISIII-GO3/174, PI080533, PI051436, PI061614, PI09–02102, and PI11/00226) and the European Union (BMH4–98–3243); Red Temática de Investigación Cooperativa en Cáncer- RD12/0036/0050-RTICC; USA-NIH-RO1-CA089715; a postdoctoral fellowship awarded to AFSA from the Fundación Científica de la AECC; Fundació Marató TV3. The work was partially supported by the Association for International Cancer Research (AICR, #09–0780, including a PhD scholarship awarded to S.M.T.). The current analyses were supported by a Colciencias PhD Scholarship, Colombia (Grant: 529/2011 to L.A.S.). This work was also supported by grants from the Instituto de Salud Carlos III FEDER, (PI11/00226) |